Dr. Flinn on Toxicities With Venetoclax Plus Obinutuzumab in CLL

Ian Flinn, MD
Published: Wednesday, Feb 14, 2018



Ian Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses the toxicities associated with the combination of venetoclax (Venclexta) and obinutuzumab (Gazyva) in chronic lymphocytic leukemia (CLL).

In a study of safety, efficacy, and minimal residual disease (MRD) negativity of the combination of venetoclax and obinutuzumab, patients with previously untreated CLL demonstrated unprecedented MRD negative rates compared to chemo-immunotherapy regimens. The combination was well tolerated, with a favorable benefit/risk profile.

Although there were some toxicities, they did not seem to be synergistic, Flinn says. The most common toxicity in this trial was neutropenia, but that is commonly seen with single-agent venetoclax and is easily manageable. One concern with venetoclax is tumor lysis syndrome, which can be a fatal complication of therapy. There was no clinical evidence of tumor lysis syndrome in this trial, Flinn says.


Ian Flinn, MD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses the toxicities associated with the combination of venetoclax (Venclexta) and obinutuzumab (Gazyva) in chronic lymphocytic leukemia (CLL).

In a study of safety, efficacy, and minimal residual disease (MRD) negativity of the combination of venetoclax and obinutuzumab, patients with previously untreated CLL demonstrated unprecedented MRD negative rates compared to chemo-immunotherapy regimens. The combination was well tolerated, with a favorable benefit/risk profile.

Although there were some toxicities, they did not seem to be synergistic, Flinn says. The most common toxicity in this trial was neutropenia, but that is commonly seen with single-agent venetoclax and is easily manageable. One concern with venetoclax is tumor lysis syndrome, which can be a fatal complication of therapy. There was no clinical evidence of tumor lysis syndrome in this trial, Flinn says.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x